ArticleTranslational lung cancer research2025
Real-world insights into atezolizumab plus bevacizumab, carboplatin, and paclitaxel for advanced non-squamous non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP) therapy demonstrated superior efficacy in advanced non-squamous non-small cell lung cancer (NSCLC) in the IMpower150 trial. However, real-world evidence on ABCP therapy remains limited. This study aimed to assess the real-world efficacy and safety of ABCP as first-line treatment for advanced non-squamous NSCLC. Methods: We retrospectively evaluated patients with advanced non-squamous NSCLC who received first-line ABCP therapy at our hospital between February 2019 and December 2021. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier methods. Objective response rate (ORR) and disease control rate (DCR) were used to evaluate the response. Results: A total of 28 patients receiving first-line ABCP were included in the efficacy analysis. The ORR and DCR were 50.0% and 92.9%, respectively. The ORR for PD-L1 [tumor population score (TPS)] ≥50%, 1-49%, and <1% was 66.7%, 50.0%, and 33.3%, respectively, while the DCR for these groups was 100%, 90.0%, and 88.9%. Patients with TPS ≥50% had significantly better OS compared to those with TPS <50% (not reached Conclusions: This study confirms the real-world efficacy and safety of ABCP therapy in patients with advanced non-squamous NSCLC. The regimen demonstrated robust tumor control across PD-L1 subgroups. The favorable safety profile, including a low incidence of pneumonitis, supports ABCP therapy as a promising treatment option with broad clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.